Diabetes Mellitus and Cardiovascular Disease

Arteriosclerosis, Thrombosis, and Vascular Biology
Ann Marie Schmidt

Abstract

Cardiovascular disease remains a leading cause of morbidity and mortality in people with types 1 or 2 diabetes mellitus. Although beneficial roles for strict control of hyperglycemia have been suggested, such a strategy is not without liabilities. Specifically, the risk of hypoglycemia and its consequences remain an omnipresent threat with such approaches. The advent of the CVOT (Cardiovascular Outcomes Trials) for new antidiabetes mellitus treatments has uncovered unexpected benefits of cardiovascular protection in some of the new classes of agents, such as the GLP-1 RAs (glucagon-like peptide-1 receptor agonists) and the SGLT-2 (sodium-glucose cotransporter-2) inhibitors. Further, state-of-the-art approaches, such as antibodies to PCKSK9 (proprotein convertase subtilisin-kexin type 9); RNA therapeutics; agents targeting distinct components of the immune/inflammatory response; and novel small molecules that block the actions of RAGE (receptor for advanced glycation end products) signaling, also hold potential as new therapies for diabetes mellitus and cardiovascular disease. Finally, interventions such as weight loss, through bariatric surgery, may hold promise for benefit in diabetes and cardiovascular disease. In this Brief ...Continue Reading

References

Apr 1, 1995·Annals of Internal Medicine·G A ColditzJ E Manson
Feb 24, 2001·Annals of Internal Medicine·V J StevensUNKNOWN Trials for the Hypertension Prevention Research Group
Nov 27, 2002·Circulation·Loredana G BucciarelliAnn Marie Schmidt
Dec 12, 2002·Diabetes·Patrick E MacDonaldMichael B Wheeler
Jun 6, 2003·The New England Journal of Medicine·David M NathanUNKNOWN Epidemiology of Diabetes Interventions and Complications Research Group
May 15, 2004·Arteriosclerosis, Thrombosis, and Vascular Biology·Allen P BurkeRenu Virmani
Dec 24, 2005·The New England Journal of Medicine·David M NathanUNKNOWN Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research
Oct 14, 2006·Arteriosclerosis, Thrombosis, and Vascular Biology·Chiara CuccurulloFrancesco Cipollone
Apr 19, 2008·Diabetes·Loredana G BucciarelliRavichandran Ramasamy
Aug 1, 2008·The Journal of Biological Chemistry·Jingjing XieAlexander Shekhtman
Aug 6, 2009·Diabetologia·UNKNOWN Control GroupM Woodward
Mar 5, 2011·Kidney International. Supplement·Masayuki Isaji
Mar 5, 2011·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·L AucottC Waweru
May 14, 2011·Structure·Jing XueAlexander Shekhtman
Dec 7, 2011·Drugs·Sang-Hyun SongYung-Jue Bang
Mar 30, 2012·The New England Journal of Medicine·W Jack RejeskiUNKNOWN Look AHEAD Research Group
Dec 5, 2012·The Journal of Experimental Medicine·Vivek RaiAnn Marie Schmidt
Dec 26, 2012·Journal of the American College of Cardiology·Stefan M NidorfPeter L Thompson
Mar 5, 2013·Clinical Chemistry and Laboratory Medicine : CCLM·Koichiro SuzukiTeruo Miyazawa
May 4, 2013·European Heart Journal·Francesco PaneniFrancesco Cosentino
Jun 26, 2013·The New England Journal of Medicine·Rena R WingSusan Z Yanovski
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators

❮ Previous
Next ❯

Citations

Aug 30, 2019·Arteriosclerosis, Thrombosis, and Vascular Biology·Yabing ChenHui Wu
Dec 18, 2019·International Journal of Molecular Sciences·Dae Yun SeoJin Han
Aug 1, 2020·Oxidative Medicine and Cellular Longevity·Jian-Kang MuXing-Xin Yang
Jun 27, 2019·Arteriosclerosis, Thrombosis, and Vascular Biology·Henry H RuizAnn Marie Schmidt
Mar 3, 2020·Frontiers in Cardiovascular Medicine·Jenny E KanterKarin E Bornfeldt
Nov 8, 2020·Protein Engineering, Design & Selection : PEDS·Christine FaustThomas Langer
Dec 5, 2020·International Journal of Biological Macromolecules·Lichun GuoWei Zhao
Jan 30, 2021·The Cochrane Database of Systematic Reviews·Mohammed AllafAbbas Dehghan
Dec 12, 2020·Diabetes Research and Clinical Practice·R Martín-PayoX González-Méndez
Jan 26, 2021·Evidence-based Complementary and Alternative Medicine : ECAM·Ju-Chi LiuHong-Jye Hong
May 20, 2020·Trends in Molecular Medicine·Nathan O StitzielKarin E Bornfeldt
Mar 19, 2021·Journal of Basic and Clinical Physiology and Pharmacology·Olawale Mathias AkinladeOlufemi Ayodele Soladoye
Mar 31, 2021·Acta Ophthalmologica·Inês Monteiro-HenriquesJoão Barbosa-Breda
Apr 2, 2021·Seminars in Thrombosis and Hemostasis·Linda M Hiebert
Apr 24, 2021·World Journal of Diabetes·Jake RajbhandariJoseph M Pappachan
Jul 9, 2021·Frontiers in Endocrinology·Vinay Singh TanwarRama Natarajan
Jul 22, 2021·Cell Metabolism·Robert H EckelIra J Goldberg
Sep 3, 2021·The Journal of Hand Surgery, European Volume·Yong-Zheng Jonathan TingMala Satku
Feb 4, 2022·Naunyn-Schmiedeberg's Archives of Pharmacology·Nikola M SobotVladimir Lj Jakovljevic

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.